Cell Line and Host Strain Development Services

inquiry

Creative Enzymes offers comprehensive Cell Line and Host Strain Development Services to support efficient, scalable, and reproducible enzyme expression. We engineer microbial and mammalian hosts to enhance productivity, stability, and product quality for research, industrial, and therapeutic applications. Our platform integrates codon optimization, vector engineering, metabolic pathway modulation, gene copy number optimization, and clonal selection strategies to establish high-performing production systems. From bacterial and yeast strain development to stable mammalian cell line generation, we provide end-to-end solutions tailored to target enzymes and regulatory requirements. Our expertise ensures consistent yields, functional integrity, and seamless scale-up for commercial enzyme manufacturing.

Cell line and host strain development

Background: The Importance of Optimized Cell Lines and Host Strains in Enzyme Production

Efficient enzyme production depends not only on gene design and expression vectors but also on the performance of the host cell or microbial strain. Native expression systems often fail to achieve desired yield, solubility, stability, or post-translational modification accuracy. As industrial enzyme applications continue to expand across pharmaceuticals, food processing, agriculture, diagnostics, and biorefineries, robust and scalable production platforms have become essential.

Host strain limitations may include:

Low transcriptional or translational efficiency.
Protease-mediated degradation.
Improper folding or aggregation.
Inadequate secretion capacity.
Insufficient cofactor biosynthesis.
Metabolic burden resulting in reduced growth or productivity.

Similarly, mammalian and insect cell systems may exhibit clonal variability, unstable gene integration, or inconsistent productivity across passages.

Cell line and host strain development addresses these challenges through genetic engineering, metabolic optimization, and rigorous selection processes. By enhancing cellular machinery and tailoring expression systems to specific enzyme requirements, production efficiency can be significantly improved while maintaining structural and functional integrity.

Creative Enzymes provides advanced host engineering solutions designed to maximize enzyme yield, ensure stability over long production cycles, and facilitate regulatory compliance for industrial and therapeutic applications.

What We Offer: Comprehensive Host Engineering and Cell Line Development Solutions

Creative Enzymes delivers integrated services covering microbial strain optimization and stable mammalian cell line generation.

Microbial Host Strain Development

Engineering of Escherichia coli strains for enhanced recombinant protein production.
Yeast strain optimization (e.g., Pichia pastoris and Saccharomyces cerevisiae).
Bacillus strain development for high-level enzyme secretion.
CRISPR/Cas-mediated genome editing.
Knockout of proteases and competing metabolic pathways.
Enhancement of chaperone systems.

Stable Mammalian Cell Line Development

Transient-to-stable cell line transition.
Gene amplification systems.
Targeted gene integration strategies.
Single-cell cloning and high-producing clone screening.
Stability studies across multiple passages.

Expression Cassette Optimization

Promoter selection and optimization.
Enhancer and regulatory element engineering.
Gene copy number optimization.
Codon optimization and mRNA stability enhancement.

Secretion and Folding Enhancement

Signal peptide screening.
ER stress reduction strategies.
Co-expression of folding catalysts.

High-Throughput Screening and Clone Selection

Automated colony screening.
Productivity assays.
Stability evaluation under industrial conditions.

Scale-Up Readiness and Process Transfer

Shake flask to bioreactor optimization.
Fermentation parameter development.
Technology transfer support.

Inquiry

Service Workflow

Workflow of cell line and host strain development service

Advanced Technologies for High-Performance Production Platforms

Genome Editing: Precise genome modification allows targeted integration and removal of unwanted genes, improving stability and reducing metabolic burden.
Protease-Deficient Strain Construction: Protease activity can degrade recombinant enzymes. We engineer host strains with reduced protease expression to increase yield and product integrity.
Metabolic Pathway Optimization: Metabolic engineering enhances precursor availability and cofactor supply, supporting higher productivity and sustained growth.
Promoter and Regulatory Element Engineering: Strong and tightly regulated promoters ensure controlled high-level expression while minimizing toxicity.
Single-Cell Cloning and High-Producing Clone Identification: Advanced screening technologies enable identification of clones with superior productivity and stability.
Stability and Consistency Studies: Long-term passage testing ensures genetic stability and consistent enzyme production across manufacturing cycles.

Contact Our Team

Why Choose Creative Enzymes for Cell Line and Host Strain Development

Extensive Experience Across Expression Systems

Our team has expertise in bacterial, yeast, insect, and mammalian platforms.

Customized Engineering Strategies

Each project is tailored to the enzyme's biochemical characteristics and commercial goals.

Advanced Genome Editing Capabilities

Precision editing ensures stable and high-performing production hosts.

High-Throughput Screening Infrastructure

Rapid identification of top-performing clones accelerates development timelines.

Scalable and Industry-Ready Solutions

Designed for smooth transition from laboratory to pilot and industrial scale.

Regulatory Awareness and Documentation Support

We provide detailed documentation to facilitate regulatory submissions.

Case Studies: Successful Host and Cell Line Development Projects

Case 1: Chromosomal Engineering of E. coli for High-Yield L-Valine Production

To overcome low titers and yields limiting industrial L-valine production, a chromosomally engineered Escherichia coli strain was developed using systems metabolic engineering. The L-valine biosynthetic pathway was strengthened through heterologous expression of a feedback-resistant acetolactate synthase and overexpression of key pathway enzymes, alongside introduction of an efficient exporter. Precursor supply was enhanced by increasing the pyruvate pool, and redox balance was optimized via cofactor-specific enzyme replacements, enabling efficient synthesis under oxygen-limited conditions. In fed-batch fermentation, the final strain produced 84 g/L L-valine with a yield of 0.41 g/g glucose, representing one of the highest reported titers in E. coli.

High-yield production of L-valine in engineered Escherichia coli by a novel two-stage fermentation Figure 1. Effects of modification of the export system on L-valine production and cell growth. Pairwise comparisons were conducted to each strain and its former strain. (Hao et al., 2020)

Case 2: Metabolic Engineering of BHK-21 Cells for Enhanced Erythropoietin Production

To improve recombinant protein productivity, BHK-21 cells were metabolically engineered through cytoplasmic expression of yeast pyruvate carboxylase (PYC2), restoring the link between glycolysis and the TCA cycle and increasing intracellular ATP levels. Following transfection with the human erythropoietin (EPO) gene, PYC2-expressing clones demonstrated a twofold increase in glucose-specific productivity and product concentration in perfusion bioreactors compared to controls. The engineered cells exhibited improved tolerance to low-glucose conditions, reduced lactate accumulation, and lower glucose consumption. Enhanced metabolic efficiency prolonged cell viability and extended the production phase by 30%, enabling more sustained and cost-effective EPO manufacturing.

Expression of recombinant cytoplasmic yeast pyruvate carboxylase for the improvement of the production of human erythropoietin by recombinant BHK-21 cells Figure 2. Distribution of the EGFP fluorescence of the control cells ((a), BHK-21-pAGEPO) and PYC2-expressing cells ((b), BHK-21-PYC2EPO) transfected with the bicistronic plasmid pSBC-EGFP-EPO. Cells of the LP interval had an intermediate expression rate, whereas cells of the HP interval showed a high expression rate. However, the high-producing cells lost their productivity within 4 weeks. (Irani et al., 2002)

Frequently Asked Questions (FAQs)

Q: What is the difference between host strain development and cell line development?

A: Host strain development typically refers to microbial systems such as bacteria or yeast, while cell line development often involves mammalian or insect cells used for complex protein production.
Q: How do you ensure long-term stability of engineered strains?

A: We conduct multi-passage stability studies, confirm gene integration integrity, and monitor productivity over extended culture periods.
Q: Can you optimize existing production strains?

A: Yes. We can improve productivity, reduce protease activity, enhance secretion efficiency, and optimize metabolic pathways in established strains.
Q: What scale of production can your engineered strains support?

A: Our strains are designed for scalability, from laboratory research batches to pilot and industrial-scale fermentation.
Q: Can multiple genes be engineered simultaneously?

A: Yes. Using advanced genome editing tools, we can integrate or modify multiple genes within a single development project.
Q: How long does development typically take?

A: Project duration depends on system complexity. Microbial strain optimization may require several weeks, while stable mammalian cell line development typically requires several months.

References:

Hao Y, Ma Q, Liu X, et al. High-yield production of L-valine in engineered Escherichia coli by a novel two-stage fermentation. Metabolic Engineering. 2020;62:198-206. doi:10.1016/j.ymben.2020.09.007
Irani N, Beccaria AJ, Wagner R. Expression of recombinant cytoplasmic yeast pyruvate carboxylase for the improvement of the production of human erythropoietin by recombinant BHK-21 cells. Journal of Biotechnology. 2002;93(3):269-282. doi:10.1016/S0168-1656(01)00409-6

First Name:

Last Name:

Email *

Phone Number:

Company/Institution:

Country or Region:

Quantity:

Services & Products of Interested

Project Description:

For research and industrial use only. Not intended for personal medicinal use. Certain food-grade products are suitable for formulation development in food and related applications.

Services

Online Inquiry